Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (33 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

33 publications

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 33 publications

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )
J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	MoPmSpVv[3Srb36gRZN{[Xl?	NX;U[m9GOC5zLUOwJO69VQ>?	NIO2e4g1QCCq		NXTUR2dHcW6mdXPld{BKS0GPLUGg[ZhxemW\|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?	MmSxNlY2OTNzN{K=
H460	NXnQNnF4TnWwY4Tpc44hSXO\|YYm=	MkfaNE4yNTNyIN88US=>	MlfzOFghcA>?		M3nVc4lv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt	NXfLdVd5OjZ3MUOxO\|I>
HKESC-2	NH;XdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonZNlDDqM7:TR?=	NUG5OWpDPDkEoHlCpC=>		NWXre5FDe2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi	NFu2UFQzPjR5NE[5Ny=>
CaES-17	NWrVU2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVWyNOKh\|ryP	NH\tSoI1QMLiaNMg		NG\DRlB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW\|IH;mJI95[WyrcHzheIlvyqB?	NH32eFkzPjR5NE[5Ny=>
HKESC-2	MVjBdI9xfG:\|aYOgRZN{[Xl?	M1PmRVIxyqEQvF2=	NXS4WVZmPDkEoHlCpC=>		M1HSUpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	MUGyOlQ4PDZ7Mx?=
CaES-17	MmHURZBweHSxc3nzJGF{e2G7	MkKxNlDDqM7:TR?=	M{XhWFQ5yqCqwrC=		M4XCXpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	NGXx[\|kzPjR5NE[5Ny=>
A549	NEKwNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;FW3lWPS1zNkCg{txO	MWO0POKhcMLi	MlvVSG1UVw>?	NIqzRW5KSzVyPUG2N{41KM7:TR?=	MWSyOlQ3PDZ2Mx?=
HCC827	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iwOFUuOTZyIN88US=>	NGC3RYQ1QMLiaNMg	NILzNY1FVVOR	NWDYRoRPUUN3ME22PU4zKM7:TR?=	NWr2PGROOjZ2NkS2OFM>
A549	M4r5NGFxd3C2b4Ppd{BCe3OjeR?=	NF;6eYE5OCEEtV2=	NXPUcXoxPDkEoHlCpC=>	MXzEUXNQ	NH7PZ4NqdmS3Y3XzJIFxd3C2b4Ppdy=>	MlWzNlY1PjR4NEO=
HCC827	NFXBSmJCeG:ydH;zbZMhSXO\|YYm=	NX\YZldbQDBiwsXN	NU\ZVlVHPDkEoHlCpC=>	NVTSfVZtTE2VTx?=	NHjDPJZqdmS3Y3XzJIFxd3C2b4Ppdy=>	NWfjTlN1OjZ2NkS2OFM>
SGC-7901/DDP	NGS4e49HfW6ldHnvckBCe3OjeR?=	MVKxNOKhyrWP	MUGyOEBp		NWPo[GlwcW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>?	MUKyOlQxPzZ3Mx?=
SGC-7901	NGXM[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXmyOOKhcMLi		NG\Qd3hKSzVyPUGxOU4xQCEQvF2=	NF3ZS5QzPjRyN{[1Ny=>
SGC-7901/DDP	M1rUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXRPIkzPMLiaNMg		MoDPTWM2OD1\|NT60OUDPxE1?	MnG2NlY1ODd4NUO=
SGC-7901/DDP	NHnFbJBCeG:ydH;zbZMhSXO\|YYm=	M3HWe\|ExyqEEtV2=	MWmyOEBp		NIi4c5hqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m\|cHzheIlv	M3zXOVI3PDB5NkWz
SGC-7901/DDP	MXjGeY5kfGmxbjDBd5NigQ>?	NITY[pIyOMLiwsXN	MW[yOEBp		MWjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>?	M{fuVFI3PDB5NkWz
SGC-7901/DDP	MYDGeY5kfGmxbjDBd5NigQ>?	MnL4NVDDqML3TR?=	MVmyOEBp		NVrpPVBG[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv	NFfUOVQzPjRyN{[1Ny=>
H357	NVvlcVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjVNHM4NjVxMUCg{txO	MVK0PEBp	MmLHSG1UVw>?	M1LHTYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg>	NYD5WJYzOjZyMEm4O\|Q>
TAF	MY\GeY5kfGmxbjDBd5NigQ>?	MlzPNVDDqML3TR?=	MY[3JIQ>		MUTh[oZm[3S\|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>?	MYWyOVk5PzF{Nx?=
TAF	MUXGeY5kfGmxbjDBd5NigQ>?	MnyzNVDDqML3TR?=	NFXH[pc{OC1zMkCgcYlv		Mn\kdI9wemy7IHHm[oVkfHNiZFHreEBxcG:\|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n	NU\Wfm5WOjV7OEexNlc>
TAF	MVrGeY5kfGmxbjDBd5NigQ>?	NWLyRW5rOTEEoNM1US=>	NGfKfJU1QCCq		M2PhVIlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	NGT2OVEzPTl6N{GyOy=>
PANC-1	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C4Z\|IxNzZyL{GwNEDPxE1?	M2rudFI1NzR6L{eyJIg>		M2rMfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MW[yOVk4OzB4Mh?=
PANC-1	M2njemZ2dmO2aX;uJGF{e2G7	NGe0VFMzOC94MD:xNFAh\|ryP	MUiyOEBp		MXLheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	NV;oepFQOjV7N{OwOlI>
HeLa	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrQXHQzOMLizszNxsA>	M3;vWFI1yqCq		MUflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	NH3MbIszPTd5MESyNy=>
SACC-83	M2Xmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TvRVIxyqEQvF5CpC=>	NULpdJl6OjUEoHi=		MWXlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	NHLjXlMzPTd5MESyNy=>
HeLa	NF3ub4FCeG:ydH;zbZMhSXO\|YYm=	NGfOT\|YzOMLizszNxsA>	NH3xdYYzPMLiaB?=		NVraUpFH\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	NXf0XZp6OjV5N{C0NlM>
SACC-83	NHHIdINCeG:ydH;zbZMhSXO\|YYm=	NVX3coxCOjEEoN88UeKh	NYjMdoxVOjUEoHi=		MlvY[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>	MXSyOVc4ODR{Mx?=
HeLa	M4[5XmZ2dmO2aX;uJGF{e2G7	NX3zdJR5OjBxNECvPFAh\|ryP	MkHNNlTDqGh?		M{flfpVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV	MXmyOVc4ODR{Mx?=
SACC-83	M2fJOGZ2dmO2aX;uJGF{e2G7	M1rDO\|IxNzRyL{iwJO69VQ>?	Mne3NlTDqGh?		NVHvN\|J3fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	Ml;UNlU4PzB2MkO=
HLCZ01	M17NOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGw5qCUPjEEoNM1US=>	NIm4VJM1QCCq	NX;5NXpyTE2VTx?=	M17vS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NUjD[GF5OjV5MkS4PVk>
HLCZ01	NF7KSpJHfW6ldHnvckBCe3OjeR?=	MV60NOKh\|ryP	M{jtPFI1KGh?	M33RNmROW09?	M13IXolv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS\|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE>	MYqyOVczPDh7OR?=
HLCZ01	NGXFU2NCeG:ydH;zbZMhSXO\|YYm=	NYHiUVZzPDEEoN88US=>	MWSyOEBp	NWrXUYFXTE2VTx?=	NImyTWtmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u\|rF?	MkX0NlU4OjR6OUm=
HLCZ01	M2LBfmZ2dmO2aX;uJGF{e2G7	MYG0NOKh\|ryP	NIXrT4gzPCCq	M1XFNWROW09?	NHPp[ZpqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW\|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE>	MmrLNlU4OjR6OUm=
MGC803	NITwcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoiwNE03OCEQvF2=	M1;VSFczKGh?		M2PmV2lEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN	NW\UfpJlOjV5MEGzO\|g>
SGC7901	NVvuS5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm5[ooxNTZyIN88US=>	MV63NkBp		MkfUTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2=	NHzQ[WQzPTdyMUO3PC=>
MGC803	NXz6SINnTnWwY4Tpc44hSXO\|YYm=	M3\sblQxyqEQvF2=	NILuVZg5NzF4L{K0JIg>		NIjsflN2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	Ml7yNlU4ODF\|N{i=
SGC7901	Mlz1SpVv[3Srb36gRZN{[Xl?	MmmzOFDDqM7:TR?=	MojGPE8yPi9{NDDo		NHrV[mZ2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	MXqyOVcxOTN5OB?=
MCF-7	NVHESYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3uXWY1OS9zMDFOwG0>	MVe3NkBp	M2nPRWROW09?	M1vVN4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w	MonQNlU3Pjd3MUC=
MDA-MB-231	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnq1NU8yOCEQvF2=	NEjnU\|E4OiCq	MUHEUXNQ	M1LDS4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w	NEXUWowzPTZ4N{WxNC=>
MDA-MB-231	Mnj2SpVv[3Srb36gRZN{[Xl?	M{DDU\|AuPDBiwsXN	NUHkZlR3PC1{NDDo		M{DPTYlv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	Ml\VNlU2QDd\|Mkm=
MCF-7	MVHGeY5kfGmxbjDBd5NigQ>?	NUK1Wnh4OC12MDFCuW0>	MnfXOE0zPCCq		NYjoUGlS\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?=	M1e2[FI2PTh5M{K5
MCF7-MX	NVnnUppJTnWwY4Tpc44hSXO\|YYm=	M3n4[VAuPDBiwsXN	NVPPUVFiPC1{NDDo		MULlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	MYWyOVU5PzN{OR?=
MDA-MB-231	MUPGeY5kfGmxbjDBd5NigQ>?	MnnPNE01OCEEtV2=	NFG1flI1NTJ2IHi=		MonEd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW\|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi	M1\KWVI2PTh5M{K5
A2780	MoP1SpVv[3Srb36gRZN{[Xl?	MlG2OU8yOC9zNTFOwG0>	MUK0PEBp		NEXpcpFl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW\|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MV:yOVQzPDh7OB?=
SKOV3	MWXGeY5kfGmxbjDBd5NigQ>?	MXu1M\|ExNzF3IN88US=>	M3qySFQ5KGh?		M2nIW4Rm[3KnYYPld{BEd3hvMjDlfJBz\XO\|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NX3KTXpQOjV2MkS4PVg>
A2780	NGi3N5FHfW6ldHnvckBCe3OjeR?=	NGG3d3Q2NzFyL{G1JO69VQ>?	MXG0PEBp		M2ntVIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	M{[5dFI2PDJ2OEm4
SKOV3	NH3LOVdHfW6ldHnvckBCe3OjeR?=	MUO1M\|ExNzF3IN88US=>	NYXGdGhEPDhiaB?=		M4[5[4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	Mn:wNlU1OjR6OUi=
A2780	NX3jNpIxTnWwY4Tpc44hSXO\|YYm=	M1O3XVUwOTBxMUWg{txO	NVzMR41VPDhiaB?=		MmTX[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw	NUO5dJRFOjV2MkS4PVg>
SKOV3	MVPGeY5kfGmxbjDBd5NigQ>?	NFjmSJE2NzFyL{G1JO69VQ>?	MXG0PEBp		Mnj2[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw	Ml[wNlU1OjR6OUi=
A2780	NULVTG1OTnWwY4Tpc44hSXO\|YYm=	NXHhS\|Z2PS9zMD:xOUDPxE1?	M13I[VEhcA>?		M3rjZ4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MlvlNlU1OjR6OUi=
SKOV3	NWW4Nlg4TnWwY4Tpc44hSXO\|YYm=	NHvCTWc2NzFyL{G1JO69VQ>?	NGW3S3YyKGh?		M4HKZolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NYnvTFMyOjV2MkS4PVg>
HCT-15	MYDGeY5kfGmxbjDBd5NigQ>?	NEjCWHMyOC13MDFOwG0>	M4SwW\|YuOzZiaB?=		MVzpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	M1vY[VI2OjF6MEK4
HT-29	NGD1W2pHfW6ldHnvckBCe3OjeR?=	NV;JToRlOTBvNUCg{txO	M2CxUVYuOzZiaB?=		MXTpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	MVmyOVIyQDB{OB?=
HSC3	NIfKV3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NH7m[WQx6oDVNECg{txO	NE\keXg1QCCq		NV2yOYxyUUN3ME2yOU42yrFzLke4NEDPxE1?	MX:yOVE6QDd6OR?=
HSC3	NW\ifVgzSXCxcITvd4l{KEG\|c3H5	MVSyOUDPxE1?	MUO0PEBp		MnXSbY5lfWOnczDhdI9xfG:\|aYO=	NWDjOINtOjVzOUi3PFk>
HSC3	NXPrV3FlTnWwY4Tpc44hSXO\|YYm=	MWiyOUDPxE1?	NIjuUoQ1QCCq		NF;tV\|BmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW	MXKyOVE6QDd6OR?=
HSC3	Mn7HSpVv[3Srb36gRZN{[Xl?	NIK1eYUzPSEQvF2=	MnraOFghcA>?		M17NWYlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=>	NWX6NWZbOjVzOUi3PFk>
HSC3	Mmq2SpVv[3Srb36gRZN{[Xl?	MU[yOUDPxE1?	NYTTU3FRPzJiaB?=		NIX4SW5l\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA>	M1uzRlI2OTl6N{i5
201T	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFLHWWk4OiCq	M{juT2ROW09?	M{LCO2lEPTB;NEiuOkDDvU1?	NXjTUlBDOjVyNUe5OFE>
273T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVTxSGwxPzJiaB?=	NHq5PXRFVVOR	MmjuTWM2OD16MD61JOK2VQ>?	MXSyOVA2Pzl2MR?=
Hep-2	NXG5[nBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYKzeXVxOzBxNUCvNVAxKM7:TR?=	NH;lNlAyOi9{ND:zOk81QCCq	MmHKSG1UVw>?	NV6xSoxIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MYiyOFk6QDV4NB?=
Hep-2	NX71U2hUSXCxcITvd4l{KEG\|c3H5	MW[1NEDPxE1?	M{PnclAuPDhiaB?=	MoLOSG1UVw>?	M3;wVolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MV6yOFk6QDV4NB?=
Hep-2	NUDQWI1pTnWwY4Tpc44hSXO\|YYm=	MVe1NEDPxE1?	M1XkWVAuPDhiaB?=	NXzxTlVmTE2VTx?=	NWrBW21OemWmdXPld{B1cGVidHXsc41memG\|ZTDhZ5Rqfmm2eTDndoFlfWGubIm=	M1fMVlI1QTl6NU[0
Hep-2	MknsSpVv[3Srb36gRZN{[Xl?	NVPnRZJUPTBizszN	MojQNE01QCCq	NU\uS4NGTE2VTx?=	M1;OWIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV	MnHXNlQ6QTh3NkS=
SGC-7901	M4\x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTkN5gyOC93MD:xNFAh\|ryP	MlmzNlQwPDhxN{KgbC=>	NF[5UHhFVVOR	MoPlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MX[yOFk6Ojl3OB?=
MKN-45	M3\vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzFWmoyOC93MD:xNFAh\|ryP	NWHNUG12OjRxNEivO\|IhcA>?	MoK4SG1UVw>?	MlXMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NGnoPYczPDl7Mkm1PC=>
SGC-7901	MmL1SpVv[3Srb36gRZN{[Xl?	MUOxNE82OC9zMECg{txO	NU\NbphsPDhiaB?=	NETwTHVFVVOR	Mlj1[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NIq4WHYzPDl7Mkm1PC=>
MKN-45	M3H6ZWZ2dmO2aX;uJGF{e2G7	MYexNE82OC9zMECg{txO	MmG1OFghcA>?	MUfEUXNQ	NYHCXVJ1\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M3TNZVI1QTl{OUW4
C666-1	MmnZR5l1d3SxeHnjbZR6KEG\|c3H5	Mk\INlAuQDBizszN	NUDaTFh[OjRiaB?=		Mnmy[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=>	M4DOcVI1QDV2OEO4
CNE-1	NE\YbWJEgXSxdH;4bYNqfHliQYPzZZk>	NIXjNoszOC16MDFOwG0>	NU\qemZFOjRiaB?=		NGrT[4Jl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	M4DYc\|I1QDV2OEO4
CNE-2	NH30N\|VEgXSxdH;4bYNqfHliQYPzZZk>	MUCyNE05OCEQvF2=	MXOyOEBp		NF36R4xl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	M13ZV\|I1QDV2OEO4
C666-1	Mn;IR5l1d3SxeHnjbZR6KEG\|c3H5	MUS2NEDPxE1?	NFjqTo04KGR?		M4HaeYVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy	NX\Ld5dLOjR6NUS4N\|g>
CNE-1	M37kcmN6fG:2b4jpZ4l1gSCDc4PhfS=>	Ml\lOlAh\|ryP	M{DMTFch\A>?		M37BSoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy	NIPyUmYzPDh3NEizPC=>
SNU-1041	NV6wRplPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D0OlAuPDBizszN	M4rkSFQ5KGh?		NE\1fFhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MkPnNlQ3QTJ5MEO=
SNU-1041	MYjGeY5kfGmxbjDBd5NigQ>?	MVyyNE8{OCEQvF2=	NICyN5I1KGh?		NIfXNJJqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	M1y2XFI1Pjl{N{Cz
SNU-1041	MkG4SpVv[3Srb36gRZN{[Xl?	NUnqeok5OC12MDFOwG0>	NY\DNHlVPCCq		NIjrcnJ2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?=	M1TtZ\|I1Pjl{N{Cz
SGC-7901	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf3OVAuOTJ3IN88US=>	M1HscFI1NzR6L{eyJIg>		MkXGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXeyOFY4PjN7NB?=
SGC-7901	MlLzRZBweHSxc3nzJGF{e2G7	NHL0WJUyODBizszN	M4\WUVczKGh?		NWDCOHQ4cW6mdXPld{BieG:ydH;zbZM>	M1TKelI1Pjd4M{m0
SGC-7901	NHzJVVNHfW6ldHnvckBCe3OjeR?=	MlvTO\|UwOTByL{GyOUDPxE1?	Mke4NlQwPDhxN{KgbC=>		MVvpcoNz\WG\|ZYOgZ4F{eGG\|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?=	NULrXZdxOjR4N{[zPVQ>
LMeC	MoX3SpVv[3Srb36gRZN{[Xl?	NXG3SopYOjBxNUCg{txO	NXfCPWw2PDhiaB?=		MoDC[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5?	NVrUb\|hmOjR4NU[3OFY>
CMeC-1	MlO1R4VtdCCYaXHibYxqfHliQYPzZZk>	MlTDNlAwPTBizszN	M4fYT\|Q5KGh?		MlmxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1PNTlI1PjV4N{S2
LMeC	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Moj0NlAwPTBizszN	Mom0OFghcA>?		NWTsc25lcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M2Ti[\|I1PjV4N{S2
CMeC-1	M1nUeWZ2dmO2aX;uJGF{e2G7	M1TVblIxNzVyIN88US=>	MV:0PEBp		M2LxUolv\HWlZYOgS\|EuWyCjcoLld5Q>	M3r1TlI1PjV4N{S2
LMeC	M3mzXGZ2dmO2aX;uJGF{e2G7	NUPGXXRzOjBxNUCg{txO	M{TaTVQ5KGh?		M3ewTolv\HWlZYOgS\|EuWyCjcoLld5Q>	NE\0UXgzPDZ3Nke0Oi=>
CMeC-1	NWi3PIpDTnWwY4Tpc44hSXO\|YYm=	NFeyV5MzOC93MDFOwG0>	M{i5fFQ5KGh?		M3r4RYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MkXiNlQ3PTZ5NE[=
LMeC	M2fKNmZ2dmO2aX;uJGF{e2G7	Mn\GNlAwPTBizszN	NETOTZU1QCCq		NH3xb4hl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkW5NlQ3PTZ5NE[=
CMeC-1	MVLGeY5kfGmxbjDBd5NigQ>?	NELYR\|czOC93MDFOwG0>	NIjaSHU1QCCq		NFnmNVhqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MUiyOFY2Pjd2Nh?=
LMeC	MWTGeY5kfGmxbjDBd5NigQ>?	NELRSpczOC93MDFOwG0>	MUS0PEBp		MoTtbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	NGf2U3czPDZ3Nke0Oi=>
OVCAR-3	MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWHGSXlDOTBiwsXN	NUmzOVFzOSCq		NH7Vb\|BmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh	MnHWNlQ2OjB{Mke=
OVCAR-3	MXnBdI9xfG:\|aYOgRZN{[Xl?	MnfnNVAhyrWP	MoHBNUBp		MYDwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA>	NHLHdYEzPDV{MEKyOy=>
OVCAR-3	M4fWZmZ2dmO2aX;uJGF{e2G7	M17CVFExKML3TR?=	M3;iclEhcA>?		NEnXRnhmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=>	MYKyOFUzODJ{Nx?=
OVCAR-3	Mkf4SpVv[3Srb36gRZN{[Xl?	MlHlNVAhyrWP	NYnJfG9LOSCq		M3KwO4Rwf25vcnXneYxifGW\|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>	NH35XG4zPDV{MEKyOy=>
OVCAR-3	MWPGeY5kfGmxbjDBd5NigQ>?	Ml\wNVAhyrWP	NF[zVFIyKGh?		M4Di[YlvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v	MWiyOFUzODJ{Nx?=
CF33	NYXnd3R6TnWwY4Tpc44hSXO\|YYm=	MXGxNFAh\|ryP	M{HDT\|I1KGh?		NYXhemg4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36=	NIHz[FgzPDVyM{e4Ni=>
CF33	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWKxNE0yODBizszN	MViwMVQh\A>?		M1v5NolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFzFb3YzPDVyM{e4Ni=>
CF33	NGrBOYJHfW6ldHnvckBCe3OjeR?=	NWLpO3hNOTBvMUCwJO69VQ>?	NF;nWVA1NTJ2IHi=		NH35VYpl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R?	NHTsZlYzPDVyM{e4Ni=>
LNCaP	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKyM\|UwOTBizszN	NWq2O3NHQTZiaB?=		NVjkdY9ScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	NILsNnozPDJ7Nkm3PC=>
LNCaP	NHvoVmZCeG:ydH;zbZMhSXO\|YYm=	M4PEPFIwPS9zMDFOwG0>	NHLRWIM6PiCq		MlzubY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6=	MVSyOFI6Pjl5OB?=
PC-3	NIHBSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqwMVUxKM7:TR?=	MnvKOFjjiImq		NIfMc5FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NWDsSWQ6OjRzMke4PFI>
PC-3	M4DDSWNmdGxiVnnhZoltcXS7IFHzd4F6	NIDqbGsxNTFyMDFOwG0>	NECyVnM4OiCq		MXvk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MYqyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib